Is Centessa Pharmaceuticals PLC ADR (CNTA) overvalued? · $6.15B cap
Centessa Pharmaceuticals PLC ADR (CNTA) is a biotechnology company listed on US.
This page asks whether Centessa Pharmaceuticals PLC ADR (CNTA) looks expensive on cached numbers — not a short thesis.
Latest reported CNTA revenue for 2024-12-31 was $0. Net income was -$235.8M. Revenue was down 100.0% from 2023-12-31 to 2024-12-31. CNTA currently screens at market cap $6.15B.
CNTA currently screens at market cap $6.15B. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next CNTA 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the CNTA stock page for the full model, not this heading.
Not investment advice.